Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial. (Q36282716)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Brief Report: Dolutegravir Plus Abacavir/Lamivudine for the Treatment of HIV-1 Infection in Antiretroviral Therapy-Naive Patients: Week 96 and Week 144 Results From the SINGLE Randomized Clinical Trial (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

anti-retroviral agent

0 references

1 reference

based on heuristic

inferred from title

abacavir/lamivudine

1 reference

based on heuristic

inferred from title

Sharon Walmsley

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Joaquín Portilla

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

author name string

Axel Baumgarten

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Juan Berenguer

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Franco Felizarta

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Marie-Aude Khuong-Josses

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

J Michael Kilby

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Thomas Lutz

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Daniel Podzamczer

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Norman Roth

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Deborah Wong

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Catherine Granier

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Brian Wynne

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Keith Pappa

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

language of work or name

0 references

publication date

1 December 2015

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Journal of Acquired Immune Deficiency Syndromes

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

70

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

515-519

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4645960

30 September 2017

Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4645960

30 September 2017

Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4645960

30 September 2017

Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4645960

22 September 2018

Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/26262777

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1097/QAI.0000000000000790

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26262777%20AND%20SRC:MED&resulttype=core&format=json

22 February 2020

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36282716&oldid=1562869251"